Drugs / CD19-BCMA Targeted CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06371040 | Jul 2024 → Nov 2025 overdue | myasthenia gravis | Ting Chang, MD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-BCMA Targeted CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06371040 ↗ |
| Action | Deplete | “CD19/BCMA CAR-T cells expanded in vivo, leading to depletion of B cells and plasma cells.” PMID 41747738 ↗ Feb 2026 |
| Modality | Cell therapy | “autologous CD19/BCMA CAR-T cells” PMID 41747738 ↗ Feb 2026 |
| Target | CD19 | “Chimeric antigen receptor (CAR) T cells targeting CD19 or B cell maturation antigen (BCMA)” PMID 41747738 ↗ Feb 2026 |